



## EOS imaging Announces Two EOS® System Installations in Paris AP-HP Public Hospitals

*Five hospitals of the Assistance Publique-Hôpitaux de Paris public hospital network now use EOS® systems for pediatric and orthopedic imaging*

**Paris, February 6, 2014** – EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging today announced two new installations of the EOS® system in AP-HP public hospitals in Paris, at the Lariboisière and Trousseau hospitals.

The Lariboisière hospital acquired an EOS® system within the framework of a healthcare cooperation consortium between the hospital and the Bachaumont private radiology center. The equipment will be used for spine and joint pathologies in adults, with a particular focus on exams associated with hip and knee arthroplasties.

The Trousseau pediatric and perinatal hospital acquired an EOS® system within the framework of the MAMUTH Musculoskeletal Diseases AP-HP initiative, which includes a multiyear clinical research program. This new EOS® system will in particular be dedicated to the imaging of osteo-articular conditions in children, amongst which those with cerebral palsy.

Marie Meynadier, CEO of EOS imaging, added: *“These two additional installations in Paris further highlight the medical value of our technology. The EOS® system is immediately usable in the patient care and treatment processes, contributing to the safety and efficiency of orthopedic diagnosis and treatment thanks to its high-quality, low-dose imaging and to the unique 3D reconstruction of the skeleton in a functional position. We are also very pleased to observe and contribute to the development of public-private partnerships enabling the installation of innovative equipment such as EOS®.”*

For further information about the Company or EOS®, the first full-body, low dose 2D/3D imaging system, please visit [www.eos-imaging.com](http://www.eos-imaging.com).

### About EOS imaging:

EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 31 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of 75 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 102 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore. For further information, please visit [www.eos-imaging.com](http://www.eos-imaging.com)

EOS imaging is listed on Compartment C of Euronext Paris  
ISIN: FR0011191766 – Ticker: EOSI

**EOSI**  
LISTED  
NYSE  
EURONEXT

Next press release: 2013 annual results on April 8, 2014 (after market).

### Contacts:

Anne Renevot  
CFO  
Ph: +33 (0)1 55 25 61 24  
[investors@eos-imaging.com](mailto:investors@eos-imaging.com)

NewCap.  
Financial communication and investor relations  
Sophie Boullila / Pierre Laurent  
Ph: +33 (0)1 44 71 94 91 - [eosimaging@newcap.fr](mailto:eosimaging@newcap.fr)

The Ruth Group (US)  
Press relations / Melanie Sollid-Penton  
Ph: 646-536-7023  
[msollid@theruthgroup.com](mailto:msollid@theruthgroup.com)